2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023.
By Nuha A. ElSayed, G. Aleppo, V. Aroda, Raveendhara R. Bannuru, F. Brown, Dennis Bruemmer, B. Collins, M. Hilliard, Diana M. Isaacs, Eric L. Johnson and 10 more. Diabetes Care, 2022
1,833 citations recorded by the source corpus.
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Subfields: Endocrinology, Diabetes and Metabolism, Genetics
View Paper: https://www.semanticscholar.org/paper/e18894f6e7283b3fe6f2fce9d25e4fcab1543ad0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- R. Rajaram
- W. Chan
- Lee-Ling Lim
- S. Vethakkan
- J. Ratnasingam
- Kee-Huat Chuah
Citations in the corpus
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review (2023, positive): “73,74 The OGTT outperforms the FPG and HbA1c in terms of accuracy in diagnosing new onset diabetes in MASH, metabolic dysfunction-associated steatohepatitis; GLP1 RA, glucagon-like peptide-1 receptor agonist; GIP RA, glucose-dependent insulinotropic polypeptide receptor agonist; SGLT2, sodium…”